Cargando…

A phase Ia/Ib clinical trial of metronomic chemotherapy based on a mathematical model of oral vinorelbine in metastatic non-small cell lung cancer and malignant pleural mesothelioma: rationale and study protocol

BACKGROUND: Metronomic oral vinorelbine is effective in metastatic NSCLC and malignant pleural mesothelioma, but all the studies published thus far were based upon a variety of empirical and possibly suboptimal schedules, with inconsistent results. Mathematical modelling showed by simulation that a...

Descripción completa

Detalles Bibliográficos
Autores principales: Elharrar, Xavier, Barbolosi, Dominique, Ciccolini, Joseph, Meille, Christophe, Faivre, Christian, Lacarelle, Bruno, André, Nicolas, Barlesi, Fabrice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4837593/
https://www.ncbi.nlm.nih.gov/pubmed/27094927
http://dx.doi.org/10.1186/s12885-016-2308-z
_version_ 1782427880089714688
author Elharrar, Xavier
Barbolosi, Dominique
Ciccolini, Joseph
Meille, Christophe
Faivre, Christian
Lacarelle, Bruno
André, Nicolas
Barlesi, Fabrice
author_facet Elharrar, Xavier
Barbolosi, Dominique
Ciccolini, Joseph
Meille, Christophe
Faivre, Christian
Lacarelle, Bruno
André, Nicolas
Barlesi, Fabrice
author_sort Elharrar, Xavier
collection PubMed
description BACKGROUND: Metronomic oral vinorelbine is effective in metastatic NSCLC and malignant pleural mesothelioma, but all the studies published thus far were based upon a variety of empirical and possibly suboptimal schedules, with inconsistent results. Mathematical modelling showed by simulation that a new metronomic protocol could lead to a better safety and efficacy profile. DESIGN: This phase Ia/Ib trial was designed to confirm safety (phase Ia) and evaluate efficacy (phase Ib) of a new metronomic oral vinorelbine schedule. Patients with metastatic NSCLC or malignant pleural mesothelioma in whom standard treatments failed and who exhibited ECOG performance status 0–2 and adequate organ function will be eligible. Our mathematical PK-PD model suggested an alternative weekly D1, D2 and D4 schedule (named Vinorelbine Theoretical Protocol) with a respective dose of 60, 30 and 60 mg. Trial recruitment will be two-staged, as 12 patients are planned to participate in phase Ia to confirm safety and consolidate the calibration of the model parameters. Depending on the phase Ia results and after a favourable decision from a consultative committee, the extension phase (phase Ib) will be an efficacy study including 20 patients who will receive the Optimal Vinorelbine Theoretical Protocol. The primary endpoint is the tolerance (assessed by CTC v4.0) for the phase Ia and the objective response according to RECIST 1.1 for phase Ib. An ancillary study on circulating angiogenesis biomarkers will be a subproject of the trial. DISCUSSION: This ongoing trial is the first to prospectively test a mathematically optimized schedule in metronomic chemotherapy. As such, this trial can be considered as a proof-of-concept study demonstrating the feasibility to run a computational-driven protocol to ensure an optimal efficacy/toxicity balance in patients with cancer. TRIAL REGISTRATION: EudraCT N°: 2015-000138-31
format Online
Article
Text
id pubmed-4837593
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-48375932016-04-21 A phase Ia/Ib clinical trial of metronomic chemotherapy based on a mathematical model of oral vinorelbine in metastatic non-small cell lung cancer and malignant pleural mesothelioma: rationale and study protocol Elharrar, Xavier Barbolosi, Dominique Ciccolini, Joseph Meille, Christophe Faivre, Christian Lacarelle, Bruno André, Nicolas Barlesi, Fabrice BMC Cancer Study Protocol BACKGROUND: Metronomic oral vinorelbine is effective in metastatic NSCLC and malignant pleural mesothelioma, but all the studies published thus far were based upon a variety of empirical and possibly suboptimal schedules, with inconsistent results. Mathematical modelling showed by simulation that a new metronomic protocol could lead to a better safety and efficacy profile. DESIGN: This phase Ia/Ib trial was designed to confirm safety (phase Ia) and evaluate efficacy (phase Ib) of a new metronomic oral vinorelbine schedule. Patients with metastatic NSCLC or malignant pleural mesothelioma in whom standard treatments failed and who exhibited ECOG performance status 0–2 and adequate organ function will be eligible. Our mathematical PK-PD model suggested an alternative weekly D1, D2 and D4 schedule (named Vinorelbine Theoretical Protocol) with a respective dose of 60, 30 and 60 mg. Trial recruitment will be two-staged, as 12 patients are planned to participate in phase Ia to confirm safety and consolidate the calibration of the model parameters. Depending on the phase Ia results and after a favourable decision from a consultative committee, the extension phase (phase Ib) will be an efficacy study including 20 patients who will receive the Optimal Vinorelbine Theoretical Protocol. The primary endpoint is the tolerance (assessed by CTC v4.0) for the phase Ia and the objective response according to RECIST 1.1 for phase Ib. An ancillary study on circulating angiogenesis biomarkers will be a subproject of the trial. DISCUSSION: This ongoing trial is the first to prospectively test a mathematically optimized schedule in metronomic chemotherapy. As such, this trial can be considered as a proof-of-concept study demonstrating the feasibility to run a computational-driven protocol to ensure an optimal efficacy/toxicity balance in patients with cancer. TRIAL REGISTRATION: EudraCT N°: 2015-000138-31 BioMed Central 2016-04-20 /pmc/articles/PMC4837593/ /pubmed/27094927 http://dx.doi.org/10.1186/s12885-016-2308-z Text en © Elharrar et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Study Protocol
Elharrar, Xavier
Barbolosi, Dominique
Ciccolini, Joseph
Meille, Christophe
Faivre, Christian
Lacarelle, Bruno
André, Nicolas
Barlesi, Fabrice
A phase Ia/Ib clinical trial of metronomic chemotherapy based on a mathematical model of oral vinorelbine in metastatic non-small cell lung cancer and malignant pleural mesothelioma: rationale and study protocol
title A phase Ia/Ib clinical trial of metronomic chemotherapy based on a mathematical model of oral vinorelbine in metastatic non-small cell lung cancer and malignant pleural mesothelioma: rationale and study protocol
title_full A phase Ia/Ib clinical trial of metronomic chemotherapy based on a mathematical model of oral vinorelbine in metastatic non-small cell lung cancer and malignant pleural mesothelioma: rationale and study protocol
title_fullStr A phase Ia/Ib clinical trial of metronomic chemotherapy based on a mathematical model of oral vinorelbine in metastatic non-small cell lung cancer and malignant pleural mesothelioma: rationale and study protocol
title_full_unstemmed A phase Ia/Ib clinical trial of metronomic chemotherapy based on a mathematical model of oral vinorelbine in metastatic non-small cell lung cancer and malignant pleural mesothelioma: rationale and study protocol
title_short A phase Ia/Ib clinical trial of metronomic chemotherapy based on a mathematical model of oral vinorelbine in metastatic non-small cell lung cancer and malignant pleural mesothelioma: rationale and study protocol
title_sort phase ia/ib clinical trial of metronomic chemotherapy based on a mathematical model of oral vinorelbine in metastatic non-small cell lung cancer and malignant pleural mesothelioma: rationale and study protocol
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4837593/
https://www.ncbi.nlm.nih.gov/pubmed/27094927
http://dx.doi.org/10.1186/s12885-016-2308-z
work_keys_str_mv AT elharrarxavier aphaseiaibclinicaltrialofmetronomicchemotherapybasedonamathematicalmodeloforalvinorelbineinmetastaticnonsmallcelllungcancerandmalignantpleuralmesotheliomarationaleandstudyprotocol
AT barbolosidominique aphaseiaibclinicaltrialofmetronomicchemotherapybasedonamathematicalmodeloforalvinorelbineinmetastaticnonsmallcelllungcancerandmalignantpleuralmesotheliomarationaleandstudyprotocol
AT ciccolinijoseph aphaseiaibclinicaltrialofmetronomicchemotherapybasedonamathematicalmodeloforalvinorelbineinmetastaticnonsmallcelllungcancerandmalignantpleuralmesotheliomarationaleandstudyprotocol
AT meillechristophe aphaseiaibclinicaltrialofmetronomicchemotherapybasedonamathematicalmodeloforalvinorelbineinmetastaticnonsmallcelllungcancerandmalignantpleuralmesotheliomarationaleandstudyprotocol
AT faivrechristian aphaseiaibclinicaltrialofmetronomicchemotherapybasedonamathematicalmodeloforalvinorelbineinmetastaticnonsmallcelllungcancerandmalignantpleuralmesotheliomarationaleandstudyprotocol
AT lacarellebruno aphaseiaibclinicaltrialofmetronomicchemotherapybasedonamathematicalmodeloforalvinorelbineinmetastaticnonsmallcelllungcancerandmalignantpleuralmesotheliomarationaleandstudyprotocol
AT andrenicolas aphaseiaibclinicaltrialofmetronomicchemotherapybasedonamathematicalmodeloforalvinorelbineinmetastaticnonsmallcelllungcancerandmalignantpleuralmesotheliomarationaleandstudyprotocol
AT barlesifabrice aphaseiaibclinicaltrialofmetronomicchemotherapybasedonamathematicalmodeloforalvinorelbineinmetastaticnonsmallcelllungcancerandmalignantpleuralmesotheliomarationaleandstudyprotocol
AT elharrarxavier phaseiaibclinicaltrialofmetronomicchemotherapybasedonamathematicalmodeloforalvinorelbineinmetastaticnonsmallcelllungcancerandmalignantpleuralmesotheliomarationaleandstudyprotocol
AT barbolosidominique phaseiaibclinicaltrialofmetronomicchemotherapybasedonamathematicalmodeloforalvinorelbineinmetastaticnonsmallcelllungcancerandmalignantpleuralmesotheliomarationaleandstudyprotocol
AT ciccolinijoseph phaseiaibclinicaltrialofmetronomicchemotherapybasedonamathematicalmodeloforalvinorelbineinmetastaticnonsmallcelllungcancerandmalignantpleuralmesotheliomarationaleandstudyprotocol
AT meillechristophe phaseiaibclinicaltrialofmetronomicchemotherapybasedonamathematicalmodeloforalvinorelbineinmetastaticnonsmallcelllungcancerandmalignantpleuralmesotheliomarationaleandstudyprotocol
AT faivrechristian phaseiaibclinicaltrialofmetronomicchemotherapybasedonamathematicalmodeloforalvinorelbineinmetastaticnonsmallcelllungcancerandmalignantpleuralmesotheliomarationaleandstudyprotocol
AT lacarellebruno phaseiaibclinicaltrialofmetronomicchemotherapybasedonamathematicalmodeloforalvinorelbineinmetastaticnonsmallcelllungcancerandmalignantpleuralmesotheliomarationaleandstudyprotocol
AT andrenicolas phaseiaibclinicaltrialofmetronomicchemotherapybasedonamathematicalmodeloforalvinorelbineinmetastaticnonsmallcelllungcancerandmalignantpleuralmesotheliomarationaleandstudyprotocol
AT barlesifabrice phaseiaibclinicaltrialofmetronomicchemotherapybasedonamathematicalmodeloforalvinorelbineinmetastaticnonsmallcelllungcancerandmalignantpleuralmesotheliomarationaleandstudyprotocol